Prognostic and immunological potential of AC012236.1/hsa-miR-30d-5p CeRNA of AVEN by integrated analysis of single-cell and bulk RNA-seq in lung adenocarcinoma.

ABSTRACT: Lung adenocarcinoma (LUAD) is the most prevalent histological subtype of non-small cell lung cancer (NSCLC) and is characterized by high mortality and limited therapeutic efficacy in advanced stages. AVEN, an apoptosis inhibitor that interacts with Bcl-xL and Apaf-1 to suppress caspase activation, has been implicated in tumour progression and drug resistance in various cancers. However, its role in LUAD remains unclear. In this study, the prognostic importance, immune microenvironment association, and regulatory mechanisms of AVEN in LUAD were comprehensively investigated using bulk RNA sequencing (RNA-seq), single-cell RNA sequencing (scRNA-seq), and experimental validation. Analysis of the TCGA and GEO datasets revealed that AVEN expression was significantly upregulated in LUAD tissues c

SUBMITTER: Yin R 

PROVIDER: S-EPMC12669768 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature